Figure 2
FASN mRNA and protein expression in cell lines and ex vivo tumor material. FASN mRNA and protein expression in the (cisplatin-resistant*) ovarian cancer cell lines, Hey, Heycis*, Igrov-1 and Skov-3 and in ex vivo tumor material relative (rel) to that in healthy fallopian tube tissue (control). (a) By qRT–PCR, all cell lines displayed FASN mRNA overexpression ranging from 56-fold to 100-fold. (b) By WB, FASN protein expression was enhanced in all cell lines (12-fold–27-fold). Representative immunoblots for FASN and β-actin (control) of each respective cell line are depicted below the graph. (c) By qRT-PCR, FASN mRNA expression was analyzed in primary cultures derived from moderately-differentiated and poorly-differentiated ovarian cancers (G2, G3 #1, and G3 #2) and healthy fallopian tube tissue (control). The cancer cells showed a median (min.–max.) 54-fold (47-fold–62-fold) FASN mRNA overexpression. (d) By WB, FASN protein expression was 11-fold– 22-fold stronger in the primary ovarian cancer cell cultures G2, G3 #1, and G3 #2. Representative immunoblots for FASN and β-actin (control) of each respective primary culture are depicted below the graph.